Drug
In10018 Ifebemtinib
In10018 Ifebemtinib: highest development phase Phase 1/2, developed by InxMed (Shanghai) Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- InxMed (Shanghai) Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| IN10018（Ifebemtinib） NCT06166836 | Phase 1/2 | Solid Tumor |
Latest
No recent events.
Follow In10018 Ifebemtinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.